Efficacy of and possible differences in tolerance to L-dopa tablets with different rates of release of the active substance.
D000284:Administration, Oral; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004361:Drug Tolerance; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D001523:Mental Disorders / Q000139:chemically induced; D009069:Movement Disorders / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy*; D013607:Tablets; D013608:Tablets, Enteric-Coated; D014839:Vomiting / Q000139:chemically induced
D013607:Tablets; D013608:Tablets, Enteric-Coated; D004295:Dihydroxyphenylalanine